drugset / Trial / NCT05700266
Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis
Phase 2/3
Unknown
1180 enrolled
The First Affiliated Hospital with Nanjing Medical University
National Natural Science Foundation of China · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
The primary goal of the clinical trial is to test the effect of oral rivaroxaban plus aspirin in patients with recent stroke/ transient ischemic attack (TIA) caused by intracranial artery stenosis. Participants will be divided into 2 groups to receive either oral rivaroxaban plus aspirin or oral clopidogrel plus aspirin. The main question it aims to answer is whether the experimental group (oral rivaroxaban plus aspirin) is superior to the control group ( oral clopidogrel plus aspirin) to lower recurrent stroke/TIA or death in these patients during 1 year of follow-up.
Timeline
- Start
- 2023-12-30
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Rivaroxaban | Other / unclassified | 2.5 mg | Oral |
| Background | Aspirin | Small molecule | 100 mg | — |